Indian stocks: Visit www.stage2stocks.com →

MaxCyte, Inc.

Stage 2 · Advancing · week 1

As of Oct 22, 2026, MaxCyte is in Stage 2, the uptrend phase, now in its first week (since Oct 21, 2026). It closed at $1.43, 18.8% below its 52-week high and above its 200-day average, which is falling.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. More about the company

$1.43
-2.72% today
$148M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is MXCT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 13w
S4 19w
S4 33w
S4 19w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S4 13w → S1 5w → S2 8w → S3 9w → S4 1w → S3 2w → S2 11w → S4 19w → S1 5w → S2 5w → S3 2w → S4 33w → S1 7w → S4 19w → S1 11w → S2 9w → S3 4w → S2 1w current
Total tracked: 165 weeks across 19 stage runs.

MXCT among Medical Devices60th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…60MXCTStage 2 · wk 142+20.2%
vs 52W High
-18.8%
$0.68 lo$1.76 hi
18.8% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 1
1w13w26w
Week 1, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
35.3%
200 DMA: $1.06 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.14x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+20.2%
3M
+32.4%
6M
+65.9%
YTD
-7.7%
1Y
-16.4%
Scan Membership
Breakout Watch
Latest: 2025-01-30
4 appearances in last 60 days. First seen: 2022-10-10.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 1 · Vol 1.14x
2026-10-21S23→2
Wk 1 · Vol 1.55x
2026-10-20S3
Wk 4 · Vol 1.59x
2026-10-19S3
Wk 4 · Vol 1.14x
2026-10-16S3
Wk 4 · Vol 1.17x
2026-10-15S3
Wk 4 · Vol 4.78x
2026-10-14S3
Wk 3 · Vol 23.17x
2026-10-13S3
Wk 3 · Vol 0.60x
2026-10-12S3
Wk 3 · Vol 0.27x
2026-10-09S3
Wk 3 · Vol 0.43x
2026-10-08S3
Wk 3 · Vol 0.85x
2026-10-07S3
Wk 2 · Vol 0.53x
Moving averages & range
50 DMA
$1.23
200 DMA
$1.06
52W High
$1.76
52W Low
$0.68
5D Low
$1.30
Resistance levels (recent highs)
20d High
$1.47
60d High
$1.47
120d High
$1.47
250d High
$1.76
Next resistance
+2.8%
to 20d High
ROE
-20.4%
Profit margin -114.8%
Dividend Yield
0.00%
P/B 1.0

MaxCyte: quick answers

What stage is MaxCyte in?

As of Oct 22, 2026, MaxCyte (MXCT) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is MaxCyte in an uptrend?

Yes. MaxCyte is in a Stage 2 uptrend. It trades 35.3% above its 200-day average, which is falling.

How far is MaxCyte from its 52-week high?

MaxCyte closed at $1.43 on Oct 22, 2026, 18.8% below its 52-week high of $1.76. Its 52-week low is $0.68.

How has MaxCyte performed over the past year?

As of Oct 22, 2026, MaxCyte is down 16.4% over the past year and down 7.7% so far in 2026.

Which sector and industry is MaxCyte in?

MaxCyte is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.